cvs health glp-1 receptor agonist weight management diabetes treatments Caremark expands coverage options for GLP-1s Patient education tips for GLP-1,

95% CI 0.57, 0.85), and heart failure hospitalizations (HR 0.65

Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations Authors Ylmaz N , Bastemir M Received 27 November 2025 Accepted for publication 13 January 2026 Published 30 January 2026 Volume 2026:19 584175 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Dr Halis Akturk Nimet Ylmaz, 1 Mehmet Bastemir 2 1 Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey

Food and Drug Administration (FDA): Has systems in place to monitor and track reports of negative events related to prescription medications, including GLP-1 receptor agonists like Ozempic, Wegovy, and other similar drugs

They aim for broader metabolic effects (lipids, weight loss, energy expenditure etc.)